News & Events

Ordinary General Meeting of Shareholders of Probiodrug AG

All proposed resolutions approved with large majority   HALLE (SAALE), Germany, 22 June 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel […]

Probiodrug to attend and present at the BIO International Convention in June 2018

HALLE (SAALE), Germany, 29 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug updated Privacy Policy

HALLE (SAALE), Germany, 25 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces today […]

Probiodrug AG reports First Quarter 2018 Business Update

HALLE (SAALE), Germany, 15 May 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today […]

Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 21 June 2018

HALLE (SAALE), Germany, 09 May 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has […]

Probiodrug positioning its pGlu-Abeta Antibody in the field of Abeta antibodies

Probiodrug co-authored a review paper entitled “Passive Aβ Immunotherapy: Current Achievements and Future Perspectives “     HALLE (SAALE), Germany, 08 May 2018 Probiodrug AG (Euronext […]

Probiodrug AG to Publish its First Quarter 2018 Business Update on 15 May 2018

HALLE (SAALE), Germany, 8 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will […]

Probiodrug to attend and present at International Conferences in May 2018

HALLE (SAALE), Germany, 04 May 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer

Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, effective May 1, 2018; Dr. Konrad Glund and Dr. Hendrik Liebers to continue […]